Walleye Capital’s Roivant Sciences ROIV Stock Holding History

Walleye Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.2K	Sell	400 -4,800	-92%	-$142K	﹤0.01%	4451
2026 Q1	$144K	Sell	5,200 -81,300	-94%	-$2.09M	﹤0.01%	3519
2025 Q4	$1.88M	Sell	86,500 -1,900	-2%	-$37.5K	0.01%	1929
2025 Q3	$1.34M	Buy	88,400 +76,500	+643%	+$947K	0.01%	1871
2025 Q2	$134K	Buy	+11,900	New	+$129K	﹤0.01%	3620
2025 Q1	–	Sell	-42,300	Closed	-$500K	–	5009
2024 Q4	$500K	Sell	42,300 -8,000	-16%	-$94.6K	﹤0.01%	2980
2024 Q3	$580K	Sell	50,300 -36,000	-42%	-$410K	﹤0.01%	3156
2024 Q2	$912K	Buy	86,300 +74,600	+638%	+$817K	﹤0.01%	2942
2024 Q1	$123K	Buy	+11,700	New	+$126K	﹤0.01%	4276

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Walleye Capital's ROIV Position: Q2 2026 in Review

Walleye Capital reduced its Roivant Sciences (ROIV) stake by 36% in Q2 2026, selling an estimated $1.64M and leaving 98,733 shares worth $3.49M. The position accounts for 0.01% of the portfolio, ranked #1063.

Walleye Capital first reported a position in ROIV in Q4 2023 and has held it in 7 quarters since. The position peaked at $5.3M in Q4 2023. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Walleye Capital held 98,733 shares of Roivant Sciences worth $3.49M as of Q2 2026.
Walleye Capital sold 55,350 Roivant Sciences shares in Q2 2026, an estimated $1.64M.
Roivant Sciences made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1063 holding.
Walleye Capital first reported a position in Roivant Sciences in Q4 2023 and has held it in 7 quarters since.
Walleye Capital's Roivant Sciences position peaked at $5.3M in Q4 2023.
500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.